|
What is a Named Patient Program?
A named patient program allows for the supply and use of unlicensed medicines under strictly limited conditions: an unlicensed product can be supplied to meet the special needs of a particular patient where a licensed equivalent does not exist.
Named Patient medicines include medicines that are not yet licensed in a territory, as well as investigational drugs awaiting approval.
Pharmarama Named Patient Programs enable you to:
- Ethically respond to global patient demand, even in locations where a medicine is awaiting approval
- Gather valuable real-life data — such as demographics and patient safety data — that can support licensing and post-launch programs
- Build early product awareness and develop relationships with opinion leaders and disease advocates
- Develop experience and gain support from regulatory agencies, patients and physicians
- Implement commercial pricing and distribution control
- Document key data for pharmacovigilance
- Legally and ethically achieve pre-launch revenue streams
Pharmarama works with leading pharmaceutical companies in establishing formally structured Named Patient Programs in the pre-launch phase of a medicine’s lifecycle. For example, Named Patient medicines may be indicated for orphan drugs, oncology, infectious disease, critical care or metabolic disease. |
|
|
